High quality personal dosimetry
The UV dosimetry system VioSpor® is used for personal radiation monitoring.
Why use UV radiation monitoring equipment on people?
People are losing faith in the sun as a healthy, vitalizing source of energy. Rightly so: in terms of frequency, skin cancer is second only in Germany to breast cancer among women and lung cancer among men. The situation is even more dramatic in Australia: here, the rate of skin cancer is four times higher than all other types of cancer combined. Changes in leisure-time activities (short breaks in sunny southern climates with skin which is still untanned, intensive use of solaria) and the effects of the continuing expansion of the ozone hole in the coming years and decades are probably the most important reasons for this development.
Yet a trend reversal is in sight; public awareness of the hazards of excessive exposure of the body to UV radiation is growing. Changed patterns of behaviour and protective measures are gaining in importance. The objective: to enjoy the benefits of the sun without taking unnecessary health risks. There can be no doubt that the most effective method of prevention is the cultivation of responsible behaviour patterns by each individual; an informed approach to UV radiation offers the ideal protection. We all react differently to UV radiation - and each of us must therefore find the right way of dealing with this radiation.
The UV dosimetry system VioSpor® facilitates the objective monitoring necessary for use as a personal dosimeter. As a biological system, it is optimized to provide precise answers to questions concerning the biological impact of a received UV radiation dose.
A further important application is in UV personal dosimetry at the workplace. Just as radiation dosimeters are routinely used to check ionizing radiation (X-ray and gamma radiation), so VioSpor® can be used as a workplace monitoring tool. The need for appropriate UV radiation monitoring is considerable, as shown by the accident statistics in occupational medicine. Although there is currently no statutory basis, a corresponding EU guideline is in the pipeline.